Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease

Table 2 Adverse outcomes of biosimilar switch leading to treatment discontinuation, n (%)

	Adalimumab originator (n = 43)	Adalimumab biosimilar switch (n = 228)	P value
Duration on biosimilar after switch (months ± SD)	-	24.4 ± 7.08	-
Discontinuation of adalimumab	7 (16.3)	27 (11.8)	0.451
Reason for discontinuation
Loss of response	2 (4.65)	14 (6.11)	1
Adverse events	2 (4.65)	10 (4.39)	1
Other patient factors	3 (6.98)1	3 (1.31)2	0.053

¹Patient factors include: Self-discontinued medication without provider consultation given patient asymptomatic, financial barriers, and self-discontinuation for undisclosed reasons.

²Patient factors include: Self-discontinued due to the coronavirus disease 2019 pandemic, stopped due to patient reporting difficulty coordinating doses, self-discontinuation for undisclosed reasons.